Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex, CRL4 
The immunomodulatory drugs (IMiDs â ) lenalidomide and pomalidomide are analogues of thalidomide and are orally active agents used for the treatment of multiple myeloma (MM), myelodysplastic syndromes associated with a deletion (del)5q abnormality and mantle cell lymphoma. As the nomenclature suggests, one of the first known properties of IMiD compounds was their immunomodulatory capacity, including cytokine modulation and T cell co-stimulation (Corral et al, 1999; Schafer et al, 2003) . Subsequently, these compounds were shown to have pleiotropic effects on a wide range of immune cells, such as natural killer (NK) cell activation and B cell and monocyte inhibition (Corral et al, 1999; Wu et al, 2008; Gandhi et al, 2013) . The modulation of T cells has been well documented, with T cell co-stimulation resulting in increased interleukin (IL)-2 production in both CD4 + and CD8 + T cells (Schafer et al, 2003) , the shift of T helper (Th) responses from Th2 to Th1, inhibition of T regulatory cells (Tregs), and improvement of immunological synapse function in follicular lymphoma and chronic lymphocytic leukaemia (CLL; Dredge et al, 2002; Galustian et al, 2008; Ramsay et al, 2008) . In a recent study of patients with KRAS-mutant metastatic colorectal cancer, lenalidomide induced a significant decrease in the percentage of CD45RA + na€ ıve T cells while increasing the percentage of HLA-DR + activated T helper cells and the percentage of total CD45RO + CD8 + memory T cytotoxic cells (Gandhi et al, 2013) . With the identification of Cereblon (encoded by gene CRBN) as a target of thalidomide, lenalidomide and pomalidomide (Ito et al, 2010; Zhu et al, 2011; Lopez-Girona et al, 2012) , the molecular mechanisms for the pleiotropic activities of the agents may be more readily elucidated. Cereblon (encoded by the CRBN gene) is the substrate receptor of the cullin 4 ring E3 ubiquitin ligase complex (CRL4 CRBN ), which is required for the teratogenic effects by thalidomide in zebrafish and chick embryos and for the antiproliferative activity of lenalidomide and pomalidomide in MM cells. Cereblon also mediates the T cell co-stimulation by lenalidomide and pomalidomide because knockdown of Cereblon expression in primary human T cells abrogates the drug-induced IL2 expression (Ito et al, 2010; Lopez-Girona et al, 2012) . Up to this point, the substrates regulated by CRL4 CRBN have been unknown. Here we report that members of the Ikaros family of transcription factors, specifically Ikaros and Aiolos (encoded by the genes IKZF1 and IKZF3 respectively), are recruited as protein substrates for CRL4 CRBN in T cells in response to lenalidomide or pomalidomide treatment. Degradation of these substrates by lenalidomide and pomalidomide results in enhanced production of IL2 and other cytokines known to regulate T cell function. Ikaros and Aiolos are biologically relevant substrates because they are known negative regulators of IL2 expression in T cells (Bandyopadhyay et al, 2007; Gandhi et al, 2010; Quintana et al, 2012) . Furthermore, the demonstration of decreased Aiolos levels in peripheral blood upon lenalidomide administration to healthy volunteers provide one of the first clinical pharmacodynamic markers for the immunomodulatory class of drug. These measurements will enable better dosing and scheduling for the emerging next generation of compounds.
Materials and methods

Cells and plasmids
Primary T cells were isolated from human leukocytes (Blood Center of New Jersey, East Orange, NJ, USA) by centrifugation through Ficoll following the 'RosetteSep' protocol (Stem Cell Technologies, Vancouver, BC, Canada). Jurkat cells were purchased from American Type Culture Collection (Manassas, VA, USA). Cells were cultured in RPMI-1640 medium (Cellgro, Manassas, VA, USA) containing 10% (V/V) heatinactivated fetal bovine serum (Gibco, Grand Island, NY, USA) supplemented with 2 mmol/l glutamine. Wild-type (WT) IKZF3 and mutant (Mt) IKZF3 were expressed in pCMV6-entry (Blue Heron Biotechnology, Bothell, WA, USA).
Ubiquitin proteomics assay
Purified human T cells from 11 donors were stimulated with anti-CD3 antibody and each donor was treated with either dimethyl sulfoxide (DMSO) or glutarimide analogue for 6 h. The 11 donors within each treatment group were pooled into two batches with 5 or 6 donors in each batch. Donors 1-6 and donors 7-11 served as biological duplicates. Protein lysates were trypsinized and ubiquitinated peptides were enriched using an anti-di-glycine antibody. Enriched peptides were detected by liquid chromatography tandem mass spectrometry -in duplicate, and quantified into raw intensities of peak height. Raw intensities were then log 2 transformed, median-centred. The missing values for each sample were imputed using the minimal intensity of the observed ubiquitin (UBI)-peptides of the sample. For identifying UBI-peptides that are significantly affected by glutarimide analogue, R package LIMMA (Smyth, 2004) was used. Peptides with raw P-value ≤ 0Á05 and absolute fold change ≥1Á5 were considered significant. All statistical analyses were carried out using R software (http://www.r-project.org/).
Primary T cell drug treatments and protein analysis
Purified T cells were stimulated with anti-CD3 antibody (eBioscience, San Diego, CA, USA) and treated with either lenalidomide or pomalidomide (Celgene Corporation, Summit, NJ, USA) for various times and concentrations. The final DMSO concentration was 0Á1%. Cells were pre-treated with 10 lmol/l MG-132 (Calbiochem Biochemicals, Billerica, MA, USA) for 30 min before drug addition. For cycloheximide treatment studies, 2Á5 9 10 6 T cells were plated per well in six-well dishes, incubated with 10 lg/ml cycloheximide (Sigma-Aldrich, St Louis, MO, USA), and treated with either DMSO, 10 lmol/l lenalidomide or 1 lmol/l pomalidomide for 0, 1Á5, 3 or 6 h. Cells were harvested, washed in phosphate-buffered saline (PBS), and cell lysates were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE; Bio-Rad, Hercules, CA, USA 
Statistical analysis
Statistical analyses for the proteomics study were carried out using R software (http://www.r-project.org/). All other statistical analyses were performed using GRAPHPAD PRISM v5.0 (GraphPad Software, La Jolla, CA, USA), with statistical significance defined as *P < 0Á05, **P < 0Á01 and ***P < 0Á001.
Results
Lenalidomide and pomalidomide promote degradation of Ikaros and Aiolos via the proteosome in a concentrationand time-dependent manner
To identify substrates of CRL4 CRBN in the presence of a thalidomide analogue, lysates from human peripheral blood mononuclear cells treated with vehicle or a cereblon-binding glutarimide-containing analogue were subjected to immunoprecipitation using the di-glycine-lysine antibody (Kim et al, 2011) and subsequent mass spectrometry to identify peptides uniquely ubiquitinated upon drug treatment. A peptide mapping to the Aiolos protein (EYNEYENIKLER) was enriched 3Á35-fold in the presence of the glutarimide analogue compared with vehicle control (Fig 1) . To investigate the effect of lenalidomide or pomalidomide on the protein expression of Aiolos and its close family member Ikaros (which has an 88% identical gene sequence), primary human T cells were treated with either of these compounds for 1, 3, 6 and 24 h. Time-dependent degradation of both Aiolos and Ikaros was observed as early as 1 h after drug treatment, with pomalidomide having a stronger effect than lenalidomide (Fig 2A left) . The Ikaros antibody detected a dominant band representing the full-length Ikaros isoform 1 (65 kDa) and a lower band (57 kDa). The full-length Ikaros band was efficiently reduced in response to compound treatment while the lower band appeared to be affected to a lesser extent. This lower band probably represents an Ikaros isoform, several of which have been previously reported (Sun et al, 1999; Iacobucci et al, 2008) . Densitometric analysis for both Aiolos and Ikaros (full-length size marked with arrow) from multiple experiments is shown in Fig 2A ( middle and right). Under identical conditions, there was no change in IKZF1 or IKZF3 gene expression as measured by real-time PCR analysis (data not shown). T cell treatment with lenalidomide or pomalidomide (0Á1-10 lmol/l) for 6 h, triggered concentration-dependent degradation of Aiolos and Ikaros. In contrast, 30-min pretreatment with the proteosome inhibitor MG-132 stabilized Aiolos and Ikaros (Fig 2B left) . Densitometric analysis of Aiolos and Ikaros from multiple experiments is shown in Fig 2B (middle and right) . These results indicate that lenalidomide or pomalidomide administration promotes the proteasome-dependent degradation of Aiolos and Ikaros in T cells.
Cereblon binds Aiolos and Ikaros in a drug-dependent manner
To determine if Aiolos and Cereblon physically interact, co-immunoprecipitation experiments were performed in HEK-293T cells overexpressing Flag-CRBN and HA-Aiolos (Fig 3A) . After immunoprecipitation with anti-Flag antibody, Aiolos protein was co-precipitated, but only in the presence of pomalidomide. Furthermore, overexpression of a mutant CRBN (YW/AA), which can no longer bind to the pomalidomide structural analogue thalidomide (Ito et al, 2010) Lysates were separated by SDS-PAGE and immunoblotted for Aiolos, Ikaros, Cereblon and Actin expression; left representative image, middle densitometry analysis of Aiolos, right densitometry analysis of Ikaros expression normalized to Actin; data shown is mean AE SEM of four experiments; *P < 0Á05, **P < 0Á01 and ***P < 0Á001 using one-way ANOVA. Len, lenalidomide; Pom, pomalidomide; SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis; SEM, standard error of the mean; ANOVA, analysis of variance.
Cereblon engagement in interactions with the transcription factors Aiolos and Ikaros, proteins that are not readily detected as substrates in the absence of drug. These interactions lead to their degradation in T cells.
Lenalidomide and pomalidomide accelerate Aiolos and Ikaros protein turnover CRL4 CRBN is an E3 ubiquitin ligase complex known to modify target substrates with ubiquitin. Therefore, because lenalidomide-or pomalidomide-mediated degradation of Aiolos and Ikaros requires the proteosome (Fig 2B) , we investigated whether lysine ubiquitination was required for drug-mediated Aiolos degradation. To prevent ubiquitination of Aiolos, a Flag-tagged mutant IKZF3 (Flag-MT-IKZF3), in which all 30 lysine residues were conservatively substituted with arginines, was constructed. Jurkat cells were transfected with either a Flag-tagged WT IKZF3, Flag-MT-IKZF3, or an empty vector control. Cells were treated with lenalidomide or pomalidomide for 24 h and extracts were analysed by Western blot for Aiolos. Drug treatment caused degradation of endogenous Aiolos and recombinant Flag-WT-Aiolos, but not of Flag-MT-Aiolos, consistent with a mechanism of degradation that involves drug-induced lysine ubiquitination (Fig 4A) . We next evaluated the effect of lenalidomide and pomalidomide on the half-life of Aiolos and Ikaros. Primary human T cells were pulsed with cycloheximide to inhibit new synthesis of Aiolos and Ikaros proteins, and treated with either DMSO, lenalidomide, or pomalidomide in a time course. Aiolos and Ikaros appeared relatively stable in vehicle-treated cells, indicating a half-life of more than 6 h ( Fig 4B, middle and right panels). By contrast, the addition of lenalidomide or pomalidomide accelerated the turnover of the proteins, resulting in a half-life for Aiolos and Ikaros of approximately 3 and 1Á5 h, respectively (Fig 4B) .
Lenalidomide and pomalidomide induced degradation of Aiolos and Ikaros is Cereblon-dependent in T Cells
The results described above suggest that lenalidomide or pomalidomide binding enables CRL4 CRBN to associate with Ikaros and Aiolos, thus enabling their ubiquitination. To investigate whether drug-induced degradation of Aiolos and Ikaros in T cells occurs in a Cereblon-dependent manner, primary T cells were transfected with an siRNA against CRBN or control siRNA. CRBN siRNA resulted in a 75% decrease in CRBN mRNA levels compared with a non-targeting siRNA control (Fig 5A) . Previous studies have established that a similar degree of knockdown leads to abrogation of lenalidomide-or pomalidomide-induced IL2 upregulation in T cells (Lopez-Girona et al, 2012) . Figure 5B demonstrates that the ability of lenalidomide or pomalidomide to induce Aiolos and Ikaros degradation in T cells was abrogated in the presence of CRBN siRNA, but not a non-targeting control siRNA. These data show that lenalidomide and pomalidomide induce degradation of Aiolos and Ikaros in a Cereblondependent manner.
Aiolos knockdown mimics lenalidomide-or pomalidomide-induced IL2 elevation in T cells
Aiolos and Ikaros are known negative regulators of the IL2 promoter in T cells (Bandyopadhyay et al, 2007; Gandhi et al, 2010; Quintana et al, 2012) . To investigate whether they are direct mediators of the known lenalidomide-and pomalidomide-induced upregulation of IL2, we knocked down Aiolos in T cells alone or in combination with drug treatment. T cells transfected with Aiolos siRNA for 24 h displayed a 61% decrease in IKZF3 RNA and a 67% decrease in Aiolos protein (Fig 6A) . Reduction of Aiolos resulted in a corresponding 2Á5 fold increase in IL2 mRNA (P < 0Á0001; Fig 6B) , confirming that Aiolos is a negative transcriptional regulator of the IL2 gene. There was a concomitant twofold increase in IL2 protein expression (P < 0Á01; Fig 6C, compare black bars within each graph). Control siRNA-treated T cells resulted in the expected enhancement of IL2 protein production as previously reported (Fig 6C, left half of graphs; Lopez-Girona et al, 2012). The Aiolos siRNA-mediated reduction in Aiolos protein expression was further augmented by the addition of drug (Fig 6D) . This correlated with the finding that the combination of lenalidomide or pomalidomide treatment and Aiolos siRNA expression further enhanced IL2 protein expression beyond that of Aiolos siRNA or drug treatment alone (Fig 6C, right half of graphs) . Even a partial loss of Aiolos resulted in the induction of IL2 and stimulation of T cells. Additional cytokines upregulated by Aiolos siRNA and further enhanced by drug treatment include IL4, IL6, IL10, IL13, granulocyte macrophage colony-stimulating factor (GM-CSF) and interferon c (IFN-c; Fig S1) . However, cytokine levels of IL8 and IL12 remained unchanged by Aiolos siRNA and/or drug treatment (Fig S2) . The Aiolos expression levels after drug treatment in the presence or absence of Aiolos siRNA indicate a reverse correlation between Aiolos expression and IL2 production (Fig 6D) . Therefore, Aiolos knockdown mimics the pharmacological effects of lenalidomide or pomalidomide on T cells.
Ikaros knockdown mimics lenalidomide or pomalidomide-induced IL2 elevation in T cells
The impact of reducing Ikaros levels in primary T cells alone or in combination with lenalidomide or pomalidomide treatment was investigated. T cells transfected with Ikaros siRNA for 24 h displayed a 35% decrease in IKZF1 mRNA and 76% decrease in Ikaros protein (Fig 7A) , resulting in an approximately threefold increase in IL2 mRNA (P < 0Á001; Fig 7B) . A concomitant increase in IL2 protein expression by approximately twofold (P < (Fig S2) . The Ikaros expression levels after drug treatment in the presence or absence of Ikaros siRNA were measured (Fig 7D) and, similar to Aiolos levels, a reverse correlation between Ikaros expression and IL2 Aiolos and Actin expression was measured after drug treatment by immunoblot. *P < 0Á05. **P < 0Á01 and ***P < 0Á001 using paired t-test. Len, lenalidomide; Pom, pomalidomide; siAiolos, Aiolos siRNA; DMSO, dimethyl sulfoxide; SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis; ELISA, enzyme-linked immunosorbent assay. production was observed. The IL2 effect in the presence of drug was likely also to be increased due to the simultaneous reduction of Aiolos and Ikaros levels. Given that reduction of either Aiolos or Ikaros levels is sufficient to elicit co-stimulation of IL2 and other cytokines in T cells, we conclude that T cell co-stimulation by lenalidomide or pomalidomide is mediated by de-repression, via induced degradation of these IKZF transcription factors.
Lenalidomide and Pomalidomide Degrade Ikaros and Aiolos
Aiolos is a pharmacodynamic marker in human volunteers receiving lenalidomide
Healthy volunteers were administered either placebo or lenalidomide at doses of 10 or 50 mg. Blood samples were drawn immediately prior to dosing (pre-dose) and 6 h post-single dose of placebo or lenalidomide. Peripheral blood mononuclear cells were isolated by Ficoll from whole blood samples and viably frozen in DMSO prior to flow cytometric analysis of Aiolos expression. Our results indicate that Aiolos expression in peripheral T cells was reduced by 18% and 32% upon administration of 10 or 50 mg lenalidomide, respectively (Fig 8) . Therefore, the effects of lenalidomide on Aiolos protein levels observed in vitro were also detected in human volunteers, suggesting that the measurement of Aiolos protein levels in peripheral blood cells can be used as a clinical biomarker of lenalidomide activity and may be used to define the dose and schedule for novel indications and next-generation compounds.
Discussion
Following the identification of Cereblon as a target of thalidomide, it was suggested that drug binding to Cereblon inhibits the E3 ligase activity of CRL4 CRBN (Ito et al, 2010) . Ikaros and Actin expression was measured by immunoblot after drug treatment. *P < 0Á05. and **P < 0Á01 using paired t-test. Len, lenalidomide; Pom, pomalidomide; siIkaros, Ikaros siRNA; DMSO, dimethyl sulfoxide; SDS-PAGE, sodium dodecyl sulphate polyacrylamide gel electrophoresis; ELISA, enzyme-linked immunosorbent assay.
In contrast, data here demonstrate that, depending upon cellular context, binding of lenalidomide or pomalidomide can promote the E3 ligase activity towards specific substrates. Here we identify the important regulators of haematological cell fate and differentiation, Ikaros and Aiolos, as substrates that interact with CRL4 CRBN consequent to lenalidomide or pomalidomide treatment. We report that lenalidomide and pomalidomide promote the concentration-and time-dependent degradation of Aiolos and Ikaros in activated T cells within hours of drug treatment (Fig 2) . This rapid degradation is independent of new protein synthesis and occurs via protein ubiquitination and proteosomal degradation (Figs 1, 2 and 4). Drug binding to Cereblon promotes its coprecipitation with Aiolos and Ikaros (Fig 3) . Furthermore, our studies confirm that Cereblon is required for Aiolos and Ikaros degradation by lenalidomide or pomalidomide, as Cereblon knockdown in T cells protects the substrate proteins from drug-induced degradation (Fig 5) . Finally, we find that lenalidomide-and pomalidomide-induced T cell co-stimulation can be the consequence of Aiolos and Ikaros degradation, consistent with effects mediated through increased association of these substrates to the E3 ligase complex upon drug binding to Cereblon. Aiolos and Ikaros knockdown studies show that both are negative regulators of IL2 production in pan CD3 + T cells (Figs 6 and 7) .
Here we propose a model whereby lenalidomide or pomalidomide binding to CRBN results in the increased ability of CRL4 CRBN to adopt Aiolos and Ikaros as substrates, thereby shifting and/or expanding the spectrum of substrates that are bound to and targeted for degradation (Fig 9) . This may be due either to a drug-induced neomorphic activity or bias towards a subset of normal substrates. X-ray crystallographic structural studies are underway to address this in more detail. The state of both T cell anergy and activation as well as T cell lineage differentiation are tightly controlled, and the Ikaros family of zinc-finger transcription factors are essential contributors to T cell fate decisions (Thomas et al, 2007) . Ikaros has been identified as a key regulator of haematopoiesis, specifically lymphoid lineage development, and is expressed from early lymphoid progenitor stages to mature T and B cells. Ikaros-deficient mice have retarded T cell development, indicating a crucial role in early lymphoid development, while Aiolos-deficient mice exhibit normal T cell development (Wang et al, 1996 (Wang et al, , 1998 Cai et al, 2009 ). Both Ikaros and Aiolos have been shown to interact with repressive nucleosome remodelling and histone deacetylation complexes (NuRD; Kim et al, 1999; Koipally et al, 1999; Gandhi et al, 2010) . In CD4 + Th1 T cells, Ikaros is a transcriptional repressor of both IL2 and IFNc, while Aiolos is specific for IL2. It is also reported that Ikaros binds and represses the IL2 promoter in anergic CD8 + T lymphocytes (Thomas et al, 2007) . In our studies in pan-CD3 + T cells, similar to Aiolos, Ikaros functions as a negative regulator of multiple cytokines including IL4, IL6, IL10, IL13, GM-CSF, TNFa and IFNc (Fig S3) but not all cytokines were affected by Ikaros siRNA (Fig S4) . The effect of lenalidomide and pomalidomide on Aiolos and Ikaros in various T cell subsets is under investigation.
The presence of these substrates in relevant cell types is as important as the presence of Cereblon for lenalidomide or pomalidomide efficacy. Therefore Aiolos and Ikaros themselves may serve as biomarkers of response which is supported by the human volunteer data (Fig 8) . In this context, it is important to note that the effects on Ikaros and Aiolos in vitro are observed at concentrations well below the clinically achievable plasma levels of both drugs doses (lenalidomide C max at the 25 mg dose is 2Á2 lmol/l and pomalidomide C max at the 4 mg dose is 270 nmol/l; Chen et al, 2007 ; http://www.pomalyst.com/docs/prescribing_infor-mation.pdf). Finally, these biomarkers will be used to define dosing and scheduling for the next generation of drugs.
In conclusion, we have furthered our knowledge of the molecular mechanism of T cell immunomodulation by lenalidomide and pomalidomide. Our findings show that these drugs promote degradation of two members of the Ikaros family of transcription factors, which probably has major implications not only for normal T cells, but also for normal B cell development, as Ikaros and Aiolos play an important role in B cell lineage commitment and differentiation (Thompson et al, 2007; Billot et al, 2010; Ma et al, 2010; Ferreir os-Vidal et al, 2013) . In addition, Aiolos is expressed in haematological tumours including, non-Hodgkin lymphoma, CLL and acute myeloid leukaemia, although their relevance in disease requires further clarification (N€ uckel et al, 2008) . Aiolos expression has been correlated with disease progression in CLL, and splice variants of Ikaros have been identified in acute lymphocytic leukaemia (Sun et al, 1999; Iacobucci et al, 2008; N€ uckel et al, 2008) . These results may have further implications in epithelial tumours where Ikaros is expressed (Yang et al, 2010) . Whether Ikaros is recruited as a substrate by the ubiquitously expressed CRL4 CRBN in solid tumours in response to lenalidomide or pomalidomide treatment remains to be shown. Understanding the full spectrum of effects of lenalidomide and pomalidomide on this important family of transcription factors and additional potentially relevant novel CRL4 CRBN substrates is critical for optimal use of these drugs in haematological malignancies, as well as for immunotherapy in oncology and autoimmune/inflammatory diseases. Defining additional substrates of consequence will be important for customizing spectra of activity with E3 ligase modulation as a novel approach.
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